Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Cancer
- Advanced Malignancies
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study consists of arms receiving ASP7517 monotherapy and arms receiving ASP7517 and pembrolizumab combination therapy in Phase 1 (dose escalation cohort) and Phase 2 (dose expansion cohort). Phase 1 (Dose Escalation Cohort): The first dose in the combination therapy arm will begin after complet...
This study consists of arms receiving ASP7517 monotherapy and arms receiving ASP7517 and pembrolizumab combination therapy in Phase 1 (dose escalation cohort) and Phase 2 (dose expansion cohort). Phase 1 (Dose Escalation Cohort): The first dose in the combination therapy arm will begin after completing the first dose in the monotherapy arm. Phase 2 (Dose Expansion Cohort): Phase 2 monotherapy and combination dose expansion cohorts will be opened after the phase 1 escalation cohort has been completed.
Tracking Information
- NCT #
- NCT04837196
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Astellas Pharma Global Development, Inc.
Get Well Soon